Attendee Testimonials

Hear why our confirmed attendees were excited to participate in the 2021 Gastrointestinal (GI) Cancer Drug Development Summit

“The summit includes a comprehensive overview of clinical advancements in GI cancers including targeted therapies and emerging immunotherapies that will be helpful in staying up to date. In addition, it will be great to network with other industry members and experts.”

 Linh Alejandro, Adagrasib GI Medical Lead, Mirati Therapeutics

“This meeting is a unique platform for industry and clinical thought leaders to present the latest innovations in their fields and discuss how they can positively impact the lives of Gastric Cancer patients.”

 Shane Olwill, Senior Vice President, Head of Translational Science, Pieris Pharmaceuticals GmbH

“With the rapid evolution of precision medicine approaches in target multiple tumor types, including gastric cancer, we as a field we need to continually work together to provide the latest learnings from our studies. Not just for the benefit of our own programs and the field in general, but to provide benefit to patients and families who are in desperate need.”

 Jason Christiansen, CTO, Boundless Bio, Inc.

“Patients with GI cancers such as MSS-CRC, PDAC, and iCCA are in great need of new treatment strategies. These cancers require collaboration throughout the drug discovery and development community in order to advance new treatment modalities. Engaging discussions involving drug development specialists, clinical leaders, patient advocates, and academic key opinion leaders have the potential to accelerate progress in these difficult-to-treat cancers.  ”

 Eric Murphy, Co-Founder & Chief Scientific Officer, Kinnate Biopharma, Inc.